FDA investigating PML in patient taking MS drug

August 31, 2013
FDA investigating PML in patient taking MS drug
The U.S. Food and Drug Administration is investigating the possible association between a rare brain infection and the multiple sclerosis drug Gilenya (fingolimod), according to a drug safety alert issued by the agency.

(HealthDay)—The U.S. Food and Drug Administration is investigating the possible association between a rare brain infection and the multiple sclerosis (MS) drug Gilenya (fingolimod), according to a drug safety alert issued by the agency.

The FDA posted its public alert after a patient in Europe diagnosed with possible MS developed progressive multifocal leukoencephalopathy (PML) after taking the drug. The patient had not previously taken Tysabri (natalizumab), which is associated with a higher risk of PML.

This is the first reported case of PML, which usually leads to death or severe disability, in a patient taking Gilenya and not previously treated with Tysabri. The drug manufacturer, Novartis, reports that about 71,000 patients have taken the drug to treat relapsing forms of MS.

"Patients should not stop taking Gilenya without first discussing any questions or concerns with their ," the agency stated. "The FDA is providing this alert while continuing to investigate the PML case, and is working with Gilenya's manufacturer, Novartis, to obtain and review all available information about this occurrence. The FDA will communicate its final conclusions and recommendations after the evaluation is complete."

Explore further: FDA clears safety test to screen Tysabri patients

More information: More Information

Related Stories

FDA clears safety test to screen Tysabri patients

January 20, 2012

(AP) -- The Food and Drug Administration on Friday approved a new diagnostic test to help identify patients who have an increased risk of developing a rare brain infection while taking Biogen Idec's multiple sclerosis drug ...

FDA issues multiple sclerosis drug alert

May 14, 2012

(HealthDay) -- The multiple sclerosis drug Gilenya (fingolimod) should not be given to patients with certain pre-existing or recent heart conditions or stroke, or those taking certain medications to correct heart rhythm problems, ...

Leukoencephalopathy risk factors ID'd for MS drug

May 17, 2012

(HealthDay) -- Drug company researchers say they've determined which multiple sclerosis patients are most vulnerable to developing a rare brain infection while taking a powerful drug called Tysabri (natalizumab).

Ingredient in new MS drug linked to serious brain disease

April 24, 2013

(HealthDay)—The active ingredient in a drug that's expected to become a popular treatment for multiple sclerosis has been linked to four European cases of a rare but sometimes fatal brain disease called progressive multifocal ...

Recommended for you

Researchers identify source of opioids' side effects

January 17, 2017

A commercially available drug may help drastically reduce two side effects of opioid painkillers—a growing tolerance and a paradoxical increased sensitivity to pain—without affecting the drugs' ability to reduce pain, ...

CVS generic competitor to EpiPen, sold at a 6th the price

January 12, 2017

CVS is now selling a rival, generic version of Mylan's EpiPen at about a sixth of its price, just months after the maker of the life-saving allergy treatment was eviscerated before Congress because of its soaring cost to ...

Many misuse OTC sleep aids: survey

December 29, 2016

(HealthDay)—People struggling with insomnia often turn to non-prescription sleep remedies that may be habit-forming and are only intended for short-term use, according to a new Consumer Reports survey.

The pill won't kill your sexual desire, researchers say

December 15, 2016

Taking the pill doesn't lower your sexual desire, contrary to popular belief, according to research published in the Journal of Sexual Medicine. The authors of the research, from the University of Kentucky and Indiana University ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.